Tuesday, March 26, 2013
OncoSec Medical Inc., of San Diego, reported positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial of its ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.